ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?

Hepatocellular carcinoma (HCC) is one of the most common causes of death from cancer and is the final stage of chronic liver disease, usually occurring in patients with cirrhosis (CP). Chronic infection with hepatitis C virus (HCV) leads to progressive liver inflammation and cirrhosis because this virus specifically affects liver tissue. Previously used interferon therapy had a relatively low efficiency and very high risks of side effects. During the period of administration of interferon (IFN) schemes it was proved that elimination of the virus significantly reduced risk of liver cancer development. Discovery of direct-acting antiviral (DAA ) drugs have revolutionized HCV therapy with virus elimination rate of more than 95 % and an excellent safety profile. However, the risk of transformation of liver cirrhosis into hepatocellular carcinoma is still high even after complete eradication of the virus. Numerous studies have shown conflicting results on the possible relationship between the use of new antiviral drugs and the increase in the frequency of newly diagnosed or recurrent hepatocellular carcinoma. Thus, the long-term prognosis in terms of risk for HCC development among patients with sustained virological response (SVR) remains unclear.

The purpose of the study was to analyze the literature on the effect of antiviral therapy of chronic hepatitis C with interferon-containing regimens and drugs of direct antiviral action on the risk of developing or recurring hepatocellular carcinoma.

Material and Methods. We analyzed publications available from PubMed, S copus, E-library, Web of S cience using the key words “hepatocellular carcinoma”, “chronic hepatitis C”, “direct-acting antiviral drugs”, “liver cirrhosis”, “interferons”, and “sustained virological response”. Of the 99 studies found, 21 were used to write a systematic review.

Results. Eradication of the virus reduces the risks of HCC. Despite reports on high risk of occurrence or recurrence of hepatocellular carcinoma in patients with cirrhosis after treatment with DAA s compared with interferon-containing regimens, there is not enough data confirming the direct link between the use of DAA s and the development of hepatocellular carcinoma. No statistically significant difference in the frequency of HCC between patients treated with interferon or DAA s was detected.

Conclusion. Eradication of the virus is the most significant factor in the prevention of HCC; therefore, treatment of CHC should not be delayed due to the risk of HCC. Patients with liver cirrhosis require a long period of follow-up, even after successful treatment of chronic hepatitis C with DAA drugs. Stratification of HCC risk requires further research.

1. World Health Organization. Hepatitis C [Internet]. URL: http https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (cited 12.10.2018г.).

2. On the state of sanitary and epidemiological wellbeing of the population in the Russian Federation in 2017: State report. Moscow, 2018. 268. (in Russian).

3. European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2014 Feb; 60(2): 392–420. doi: 10.1016/j.jhep.2013.11.003.

4. Lafaro K.J., Demirjian A.N., Pawlik T.M. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015 Jan; 24(1): 1–17. doi: 10.1016/j.soc.2014.09.001.

5. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–86. doi: 10.1002/ijc.29210.

6. Li D., Chung R. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015 Sep 1; 121(17): 2874–82. doi: 10.1002/cncr.29528.

7. Bruno S., Zuin M., Crosignani A., Rossi S., Zadra F., Roffi L., Borzio M., Redaelli A., Chiesa A., Silini E.M., Almasio P.L., Maisonneuve P. Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study. Am J Gastroenterol. 2009 May; 104(5): 1147–58. doi: 10.1038/ajg.2009.31.

8. Lafaro K.J., Demirjian A.N., Pawlik T.M. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015 Jan; 24(1): 1–17. doi: 10.1016/j.soc.2014.09.001.

9. London W.T., Petrick J.L., McGlynn K.A. Liver cancer. Cancer Epidemiology and Prevention. 4th ed. New York: Oxford University Press, 2018. 635–660.

10. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.

11. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. 250. (in Russian).

12. Chissov V.I., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2007 (morbidity and mortality). Moscow, 2009. 245. (in Russian).

13. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol. 2011 Aug; 55(2): 245–64. doi: 10.1016/j.jhep.2011.02.023.

14. Niederau C., Hüppe D., Zehnter E., Möller B., Heyne R., Christensen S., Pfaff R., Theilmeier A., Alshuth U., Mauss S. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol. 2012 Mar 28; 18(12): 1339–47. doi: 10.3748/wjg.v18.i12.1339.

15. Hiramatsu N., Oze T., Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015 Jan; 45(2): 152–61. doi: 10.1111/hepr.12393.

16. Yu M.L., Lin S.M., Chuang W.L., Dai C.Y., Wang J.H., Lu S.N., Sheen I.S., Chang W.Y., Lee C.M., Liaw Y.F. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther. 2006; 11(8): 985–94.

17. Singal A.K., Singh A., Jaganmohan S., Guturu P., Mummadi R., Kuo Y.F., Sood G.K. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virusrelated cirrhosis. Clin Gastroenterol Hepatol. 2010 Feb; 8(2): 192–9. doi: 10.1016/j.cgh.2009.10.026.

18. Rutter K., Stättermayer A.F., Beinhardt S., Scherzer T.M., SteindlMunda P., Trauner M., Ferenci P., Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015 Mar; 41(6): 521–31. doi: 10.1111/apt.13085.

19. Janjua N.Z., Chong M., Kuo M., Woods R., Wong J., Yoshida E.M., Sherman M., Butt Z.A., Samji H., Cook D., Yu A., Alvarez M., Tyndall M., Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017 Mar; 66(3): 504–513. doi: 10.1016/j.jhep.2016.10.028.

20. Morgan T.R., Ghany M.G., Kim H.Y., Snow K.K., Shiffman M.L., De Santo J.L., Lee W.M., Di Bisceglie A.M., Bonkovsky H.L., Dienstag J.L., Morishima C., Lindsay K.L., Lok A.S.; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3): 833–44. doi: 10.1002/hep.23744.

21. van der Meer A.J., Veldt B.J., Feld J.J., Wedemeyer H., Dufour J.F., Lammert F., Duarte-Rojo A., Heathcote E.J., Manns M.P., Kuske L., Zeuzem S., Hofmann W.P., de Knegt R.J., Hansen B.E., Janssen H.L. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA. 2012 Dec 26; 308(24): 2584–93. doi: 10.1001/jama.2012.144878.

22. Yoshida H., Tateishi R., Arakawa Y., Sata M., Fujiyama S., Nishiguchi S., Ishibashi H., Yamada G., Yokosuka O., Shiratori Y., Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425–430.

23. Morgan R.L., Baack B., Smith B.D., Yartel A., Pitasi M., FalckYtter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013 Mar 5; 158(5 Pt 1): 329–37. doi: 10.7326/0003-4819158-5-201303050-00005.

24. Bartenschlager R., Lohmann V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013 Jul; 11(7): 482–96. doi: 10.1038/nrmicro3046.

25. Kim W.R., Lake J.R., Smith J.M., Skeans M.A., Schladt D.P., Edwards E.B., Harper A.M., Wainright J.L., Snyder J.J., Israni A.K., Kasiske B.L. OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant. 2015 Jan; 15 Suppl 2: 1–28. doi: 10.1111/ajt.13197.

26. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Aug; 69(2): 461–511. doi: 10.1016/j.jhep.2018.03.026.

27. Reig M., Mariño Z., Perelló C., Iñarrairaegui M., Ribeiro A., Lens S., Díaz A., Vilana R., Darnell A., Varela M., Sangro B., Calleja J.L., Forns X., Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016 Oct; 65(4): 719–726. doi: 10.1016/j.jhep.2016.04.008.

28. Conti F., Buonfiglioli F., Scuteri A., Crespi C., Bolondi L., Caraceni P., Foschi F.G., Lenzi M., Mazzella G., Verucchi G., Andreone P., Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCVrelated cirrhosis treated with direct-acting antivirals. J Hepatol. 2016 Oct; 65(4): 727–733. doi: 10.1016/j.jhep.2016.06.015.

29. Waziry R., Hajarizadeh B., Grebely J., Amin J., Law M., Danta M., George J., Dore G. Hepatocellular carcinoma risk following directacting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017 Dec; 67(6): 1204–1212. doi: 10.1016/j.jhep.2017.07.025.

30. Kanwal F., Kramer J., Asch S.M., Chayanupatkul M., Cao Y., El-Serag H.B. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 Oct; 153(4): 996–1005.e1. doi: 10.1053/j.gastro.2017.06.012.

31. Innes H., Barclay S.T., Hayes P.C., Fraser A., Dillon J.F., Stanley A., Bathgate A., McDonald S.A., Goldberg D., Valerio H., Fox R., Kennedy N., Bramley P., Hutchinson S.J. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. J Hepatol. 2018 Apr; 68(4): 646–654. doi: 10.1016/j.jhep.2017.10.033.

32. Singer A.W., Reddy K.R., Telep L.E., Osinusi A.O., Brainard D.M., Buti M., Chokkalingam A.P. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018 May; 47(9): 1278–1287. doi: 10.1111/apt.14593.

33. ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016 Oct; 65(4): 734–740. doi: 10.1016/j.jhep.2016.05.045.

34. Cabibbo G., Petta S., Calvaruso V., Cacciola I., Cannavò M.R., Madonia S., Distefano M., Larocca L., Prestileo T., Tinè F., Bertino G., Giannitrapani L., Benanti F., Licata A., Scalisi I., Mazzola G., Cartabellotta F., Alessi N., Barbàra M., Russello M., Scifo G., Squadrito G., Raimondo G., Craxì A., Di Marco V., Cammà C.; Rete Sicilia Selezione Terapia HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017 Oct; 46(7): 688–695. doi: 10.1111/apt.14256.

35. Calvaruso V., Petta S., Cacciola I., Cabibbo G. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Digestive and Liver Disease. 2018; 50(1): 12. doi: 10.1016/j.dld.2018.01.005.

36. Belli L.S., Perricone G., Adam R., Cortesi P.A., Strazzabosco M., Facchetti R., Karam V., Salizzoni M., Andujar R.L., Fondevila C., De Simone P., Morelli C., Fabregat-Prous J., Samuel D., Agarwaal K., Moreno Gonzales E., Charco R., Zieniewicz K., De Carlis L., Duvoux C.; all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAA in liver transplantation: major effects on the evolution of the indications and results. A study based on ELTR registry. J Hepatol. 2018 Oct; 69(4): 810–817. doi: 10.1016/j.jhep.2018.06.010.